Diagnosis, Prevention, Treatment and Surveillance of Anthracycline-Induced Cardiovascular Toxicity in Pediatric Cancer Survivors
Advances in pediatric cancer therapies have dramatically improved the likelihood of survival. As survivors are aging, however, we are now understanding that treatment carries a significant risk of cardiovascular toxicity, which can develop immediately, or even many years after completing therapy. An...
Main Authors: | Valerie Curren, Niti Dham, Christopher Spurney |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Hearts |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-3846/2/1/5 |
Similar Items
-
Novel Therapeutics for Anthracycline Induced Cardiotoxicity
by: Jacqueline T. Vuong, et al.
Published: (2022-04-01) -
Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
by: Neha Bansal, et al.
Published: (2019-12-01) -
Early myocardial oedema can predict subsequent cardiomyopathy in high‐dose anthracycline therapy
by: Fabian Muehlberg, et al.
Published: (2023-02-01) -
Electrocardiograms for cardiomyopathy risk stratification in children with anthracycline exposure
by: Lajja Desai, et al.
Published: (2019-08-01) -
Predictive Factors of Therapy-Related Cardiovascular Events in Patients with Lymphoma Receiving Anthracyclines
by: Alberto Lopez-Garcia, et al.
Published: (2024-04-01)